Status:
UNKNOWN
Efficacy and Safety of Topical Cysteamine for Postinflammatory Hyperpigmentation
Lead Sponsor:
Chang Gung Memorial Hospital
Collaborating Sponsors:
Scientis Pharma SA
Conditions:
Hyperpigmentation; Postinflammatory
Eligibility:
All Genders
20+ years
Phase:
NA
Brief Summary
Post-inflammatory hyperpigmentation is a common pigmentary skin disorder that is refractory to treatment. The treatment for postinflammatory hyperpigmentation is limited. Recent studies have shown tha...
Detailed Description
Post-inflammatory hyperpigmentation is a common pigmentary skin disorder that is refractory to treatment and troublesome for darker skin individuals. The current treatment with conventional bleaching ...
Eligibility Criteria
Inclusion
- Over 20 years old
- Patients with postinflammatory hyperpigmentation for more than 3 months.
Exclusion
- Patients with topical hydroquinone, oral tranexamic acid and/or other skin whitening agents.
- Patients that receive or planning to receive laser treatment for spot removal during the study period.
- Individuals with allergic history to cysteamine or vehicle ingredients.
- Pregnant patients or patients planning to become pregnant during the time of the study.
Key Trial Info
Start Date :
December 10 2021
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 10 2022
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT05206318
Start Date
December 10 2021
End Date
December 10 2022
Last Update
January 25 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Linkou Chang Gung Memorial Hospital
Taoyuan, Taiwan, 33305